2023 World Conference on Lung Cancer (Posters)-EP11.02. Nivolumab as Maintenance Therapy Following Platinum-Based Chemotherapy in EGFR-mutant Lung Cancer Patients After TKI Failure

EP11.02. Nivolumab as Maintenance Therapy Following Platinum-Based Chemotherapy in EGFR-mutant Lung Cancer Patients After TKI Failure - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to examine the efficacy of nivolumab, an immunotherapy drug, as maintenance therapy in patients with non-small cell lung cancer (NSCLC) who have a mutation in the epidermal growth factor receptor (EGFR) and have failed treatment with EGFR-tyrosine kinase inhibitors (TKIs). The study involved 26 patients who received platinum-based chemotherapy followed by nivolumab maintenance therapy. The primary endpoint was progression-free survival (PFS), and secondary outcomes included overall survival (OS) and treatment-related adverse events.<br /><br />The results of the study showed that nivolumab maintenance therapy did not provide clinical benefits to patients with EGFR-mutant NSCLC after they failed treatment with EGFR-TKIs. The median OS was 24.8 months. The study also analyzed the baseline characteristics of the patients and found no significant differences between the responders and non-responders to the treatment.<br /><br />These findings are important because they suggest that immunotherapy alone may not be effective in this specific patient population. Further research and investigation are needed to identify alternative treatment options for patients with EGFR-mutant NSCLC who have failed EGFR-TKI therapy. It is clear that disease progression is still a challenge in targeted therapy, and combining immunotherapy with other treatment modalities, such as chemotherapy or radiotherapy, may hold promise in improving outcomes.<br /><br />In summary, nivolumab maintenance therapy following platinum-based chemotherapy did not demonstrate clinical benefits in patients with EGFR-mutant NSCLC who had previously failed EGFR-TKI therapy. The study highlights the need for additional research to explore alternative treatment strategies for this patient population.

Asset Subtitle

Jiwon Kim

Meta Tag

Speaker Jiwon Kim

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

nivolumab

immunotherapy

maintenance therapy

non-small cell lung cancer

NSCLC

epidermal growth factor receptor

EGFR

EGFR-tyrosine kinase inhibitors

progression-free survival

overall survival